SCHEMBL3971417

SCHEMBL3971417

C=CCOc1cc[c]cc1OC

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.46
ALDH1A1 P00352 6/20 0.40
CYP2D6 P10635 2/20 0.40
POLB P06746 2/20 0.39
HPGD P15428 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
KMT2A Q03164 3/20 0.38
GAA P10253 3/20 0.38
MEN1 O00255 2/20 0.38
MAPT P10636 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
HSD17B10 Q99714 1/20 0.38
PDE4B Q07343 3/20 0.36
PDE4A P27815 1/20 0.36
PDE4C Q08493 1/20 0.36
PDE4D Q08499 1/20 0.36
G6PD P11413 1/20 0.36
MGAM O43451 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7688247 0.93 KDM4E (0.42) KDM4EALDH1A1CYP2D6POLBHPGD
SCHEMBL3464239 0.89 HPGD (0.39) KDM4EALDH1A1CYP2D6HPGDGAA
SCHEMBL6601793 0.82 ALDH1A1 (0.41) KDM4EALDH1A1CYP2D6HPGDKMT2A
SCHEMBL6197092 0.82 ALDH1A1 (0.41) KDM4EALDH1A1CYP2D6HPGDKMT2A
SCHEMBL8717334 0.81 POLB (0.31) KDM4EALDH1A1POLBHPGDL3MBTL1
SCHEMBL3202848 0.80 MTNR1A (0.48) KDM4ECYP2D6GAAMAPTHSD17B10
SCHEMBL7355064 0.79
SCHEMBL8350925 0.79
SCHEMBL8350928 0.79
SCHEMBL3554452 0.79 TSHR (0.33) KDM4EALDH1A1CYP2D6HPGDKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070276011-A1 Plasminogen Activator Inhibitor-1 Inhibitor INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) 2007-11-29 US claimed
EP-1666469-A1 PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR Institute of Medicinal Molecular Design, Inc. (JP) 2006-06-07 EP claimed
CN-111183143-B Compound, substrate for pattern formation, photodegradable coupling agent, pattern formation method, and method for manufacturing transistor 株式会社 尼康 2023-04-04 CN disclosed
CN-110198946-B Compound, substrate for pattern formation, photodegradable coupling agent, pattern formation method, and method for manufacturing transistor 株式会社尼康 2022-04-26 CN disclosed
CN-111183143-A Compound, substrate for pattern formation, photodegradable coupling agent, pattern formation method, and method for manufacturing transistor 株式会社尼康 2020-05-19 CN disclosed
EP-1951215-A4 HYDRAZONE DERIVATIVES AND USES THEREOF REDPOINT BIO CORP (US) 2009-07-29 EP disclosed
EP-1951215-A2 HYDRAZONE DERIVATIVES AND USES THEREOF Redpoint Bio Corporation (US) 2008-08-06 EP disclosed
US-20070276011-A1 Plasminogen Activator Inhibitor-1 Inhibitor INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) 2007-11-29 US disclosed
US-20070207093-A1 Hydrazone derivatives and uses thereof LINQUAGEN CORP. 2007-09-06 US disclosed
WO-2007056159-A2 HYDRAZONE DERIVATIVES AND USES THEREOF REDPOINT BIO CORPORATION (US) 2007-05-18 WO disclosed
EP-1666469-A1 PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR Institute of Medicinal Molecular Design, Inc. (JP) 2006-06-07 EP disclosed
US-5256668-A Aminopyrimidine derivatives as antiviral agents for respiratory syncytial virus AMERICAN HOME PRODUCTS CORPORATION (US) 1993-10-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070276011-A1 Plasminogen Activator Inhibitor-1 Inhibitor SERPINE1, SERPINC1, SERPINB1 KDM4E 3789/4885ALDH1A1 1861/4885CYP2D6 4216/4885
US-20070207093-A1 Hydrazone derivatives and uses thereof TAS2R1, TAS2R5, TAS1R1 KDM4E 3193/4885ALDH1A1 72/4885CYP2D6 1470/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.